Crystal (gentian) violet chemical review

Completed

Crystal (gentian) violet was formerly used in Australia as a preservative, fungicide, bactericide and anthelmintic and as an indicator dye in veterinary preparations and animal feeds.

Work plan

Work plan

Click on the tabs for more information about the status of each phase in the review process. For more information about how each phase is conducted, please read about the reconsideration process.

Chemicals

  • Crystal (gentian) violet
1. Nomination

1. Nomination

Phase status

Completed

In January 1991 the Pesticides and Agricultural Chemicals Standing Committee of the National Health and Medical Research Council (NHMRC) asked the Australian Agricultural and Veterinary Chemicals Council to withdraw all clearances and maximum residue limits (MRLs) for crystal (gentian) violet. Concerns had been held for some time about the toxicity of crystal (gentian) violet, based on data that demonstrated that it was a potential carcinogen.

The APVMA (then the NRA) reviewed the use of crystal violet because of concerns about its carcinogenicity potential and possible risks to public health.

2. Prioritisation

2. Prioritisation

Phase status

Completed
3. Scoping and work plan

3. Scoping and work plan

Phase status

Completed
4. Notice of reconsideration

4. Notice of reconsideration

Phase status

Completed
5. Assessment

5. Assessment

Phase status

Completed
6. Proposed regulatory decision

6. Proposed regulatory decision

Phase status

Completed

In March 1993, the NHMRC placed crystal (gentian) violet in schedule 4 of the Standard for the Uniform Scheduling of Medicines and Poisons. Schedule 4 applies to ‘Prescription Only Medicine’. The NHMRC recommended that the APVMA (then the NRA) withdraw all clearances for the use of crystal (gentian) violet as a marker dye and as an active constituent.

According to the NHMRC, ‘Crystal violet demonstrated carcinogenic/tumorigenic effects in mice in life-span studies. Hepatocellular carcinoma, adenoma of the Harderian gland and Type A reticular cell sarcomas in multiple sites were found in 18–24-month-old mice, and in vitro studies revealed that crystal (gentian) violet) is a mutagen and clastogen’.

In January 1994 the APVMA began a special review of crystal (gentian) violet to formally consolidate the previous regulatory action by the Pesticides and Agricultural Chemicals Standing Committee, the Australian Agricultural and Veterinary Chemicals Council and the NHMRC.

7. Consultation

7. Consultation

Phase status

Completed
8. Final regulatory decision

8. Final regulatory decision

Phase status

Completed

The APVMA completed the special review of crystal (gentian) violet in September 1994 but did not publish a final report. The APVMA found that the data demonstrated that crystal (gentian) violet posed a potential risk to public health.

The APVMA:

  • cancelled the clearance certificates for crystal (gentian) violet, with effect from 1 November 1994
  • cancelled the MRLs for crystal (gentian) violet, with effect from 1 November 1994
  • cancelled all registrations and relevant approvals of veterinary products containing crystal (gentian) violet, with effect from 1 November 1994.

No veterinary products containing crystal (gentian) violet are currently registered for use in Australia.

Contact the APVMA for copies of the APVMA Gazette notice: Cancellation of registration for agricultural products.

9. Implementation

9. Implementation

Phase status

Completed
Publication archive
Was this page helpful?

Your feedback will be submitted to the APVMA anonymously. If you require a response, please contact us.

CAPTCHA